ReviewFrontiers in pharmacology2026
Endoplasmic reticulum stress in steroid-induced osteonecrosis: translational bottlenecks and targeted therapeutic strategies.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-induced osteonecrosis of the femoral head (SONFH) is a crippling orthopedic disease. While glucocorticoids are a well-established etiological factor, the molecular framework driving the cascading tissue destruction remains elusive. Endoplasmic reticulum stress (ERS) has emerged as a central pathogenic hub. This review comprehensively synthesizes current evidence on how ERS orchestrates the multi-dimensional pathological network in SONFH, focusing on specific signaling paradoxes and translational barriers. Mechanistically, ERS drives irreversible osteoblast apoptosis via the PERK-CHOP axis and impairs endothelial regeneration by suppressing mTOR signaling. Notably, ERS exhibits profound microenvironmental heterogeneity: in articular chondrocytes, it aberrantly stabilizes HIF-1α to precipitate matrix degradation-a stark contrast to its canonical vasculoprotective role. Furthermore, ERS exacerbates intraosseous ischemia through a positive feedback loop with lipid metabolism. Importantly, we identify the "ischemic island" effect (a physical sclerotic barrier) and inherent biomechanical discrepancies in quadrupedal animal models as primary bottlenecks hindering the clinical translation of potent ERS inhibitors. To bridge this translational chasm, we propose combinatorial interventions coupling ERS modulators with advanced bone-targeted delivery systems (e.g., Asp8-modified nanocarriers) to breach the ischemic barrier, offering a pivotal strategy for future precision joint-preserving therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.